Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice

Psychopharmacology (Berl). 2018 Apr;235(4):1151-1161. doi: 10.1007/s00213-018-4832-9. Epub 2018 Jan 26.

Abstract

Rationale: Associated with frank neuropathology, patients with Alzheimer's disease suffer from a host of neuropsychiatric symptoms that include depression, apathy, agitation, and aggression. Negative allosteric modulators (NAMs) of α5-containing GABAA receptors have been suggested to be a novel target for antidepressant action. We hypothesized that pharmacological modulation of this target would engender increased motivation in stressful environments.

Methods: We utilized electrophysiological recordings from Xenopus oocytes and behavioral measures in mice to address this hypothesis.

Results: In the forced-swim assay in mice that detects antidepressant drugs, the α5β3γ2 GABAΑ receptor NAM, RY-080 produced a marked antidepressant phenotype. Another compound, PWZ-029, was characterized as an α5β3γ2 receptor NAM of lower intrinsic efficacy in electrophysiological studies in Xenopus oocytes. In contrast to RY-080, PWZ-029 was only moderately active in the forced-swim assay and the α5β3γ2 receptor antagonist, Xli-093, was not active at all. The effects of RY-080 were prevented by the non-selective benzodiazepine receptor antagonist flumazenil as well as by the selective ligands, PWZ-029 and Xli-093. These findings demonstrate that this effect of RY-080 is driven by negative allosteric modulation of α5βγ2 GABAA receptors. RY-080 was not active in the tail-suspension test. We also demonstrated a reduction in the age-dependent hyperactivity exhibited by transgenic mice that accumulate pathological tau (rTg4510 mice) by RY-080. The decrease in hyperactivity by RY-080 was selective for the hyperactivity of the rTg4510 mice since the locomotion of control strains of mice were not significantly affected by RY-080.

Conclusions: α5βγ2 GABAA receptor NAMs might function as a pharmacological treatment for mood, amotivational syndromes, and psychomotor agitation in patients with Alzheimer's and other neurodegenerative disorders.

Keywords: Agitation; Alpha 5-containing GABAA receptors; Antidepressant; Tau-Depositing Mice; rTg4510 mice.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / drug effects*
  • Aging / physiology
  • Allosteric Regulation / drug effects
  • Allosteric Regulation / physiology
  • Animals
  • Antidepressive Agents / pharmacology*
  • Benzodiazepines / pharmacology
  • Benzodiazepines / therapeutic use
  • Depressive Disorder / drug therapy
  • Depressive Disorder / psychology
  • Dose-Response Relationship, Drug
  • Female
  • Flumazenil / pharmacology
  • Flumazenil / therapeutic use
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Psychomotor Agitation / drug therapy*
  • Psychomotor Agitation / genetics
  • Receptors, GABA-A / physiology*
  • Xenopus laevis
  • tau Proteins / antagonists & inhibitors*
  • tau Proteins / genetics

Substances

  • Antidepressive Agents
  • Gabra5 protein, mouse
  • PWZ-029
  • Receptors, GABA-A
  • tau Proteins
  • Benzodiazepines
  • Flumazenil